Get regular updates to your inbox.
Meitheal Pharmaceuticals has entered into an agreement with Xentria to market XTMAB-16, the investigational treatment for pulmonary sarcoidosis, should it be approved in the future. Under the terms of the agreement, Meitheal gains the sole rights to sell and distribute XTMAB-16 in North America. Xentria retains the…
Molecure is seeking permission from the U.S. Food and Drug Administration (FDA) to conduct a Phase 2 clinical trial of its oral treatment candidate OATD-01 in people with pulmonary sarcoidosis. The request came in the form of an investigational new drug application (IND) submitted to the FDA. Should…
Sarcoidosis patients who are male or carry a genetic variation called HLA-DRB1*07 are more likely to have lymphopenia — low levels of white blood cells called lymphocytes — a known risk factor for more severe disease. That is according to a study, “Peripheral blood lymphopenia in sarcoidosis…
Greater exposure to the experimental treatment efzofitimod led to a more pronounced improvement in lung function for people with pulmonary sarcoidosis in a Phase 1/2 clinical trial, according to a new analysis. Scientists at aTyr Pharma, the company developing the first-in-class immunomodulatory therapy, presented their findings at…
Despite advances in testing, fewer than one of every six people evaluated for suspected neurosarcoidosis — sarcoidosis affecting the nervous system — received a definite diagnosis of the inflammatory disorder, according to a 30-year study in Sweden. A confirmed neurosarcoidosis diagnosis in those cases was made only following a…
Patient and physician education, trust-building, and support mechanisms are needed to reduce barriers to clinical trial participation for Black people with sarcoidosis, according to a paper by the Foundation for Sarcoidosis Research (FRS). The white paper was titled “Ignore No More Campaign on Clinical Trials…
Bellerophon Therapeutics is working toward launching a new Phase 2 trial to test INOpulse, its experimental device for inhaled nitric oxide, in people who develop pulmonary hypertension as a complication of sarcoidosis (PH-Sarc). The announcement was part of a company’s clinical program update that stated…
About six months with Acthar Gel were associated with greater therapeutic benefits than a placebo in people with pulmonary sarcoidosis receiving standard-of-care therapies, including glucocorticoids, data from a Phase 4 trial show. The benefits were sustained in those who continued treatment in an extension phase and became evident…
Swelling of a specific vein in the brain may be a sign of neurosarcoidosis, a form of sarcoidosis that affects the nervous system, a new study suggests. “Incorporating this in the current diagnostic criteria may result in timely intervention, and we encourage radiologists to look for this marker in patients…
Only about half of sarcoidosis patients showing signs of muscle disease, or myopathy, have the small clumps of immune cells in their muscles that characterize sarcoidosis, a study showed. When these clumps, called granulomas, weren’t present with muscle symptoms, myopathy was most often linked to inclusion body myositis (IBM),…
Get regular updates to your inbox.